Keith-Harrison Dewedoff
Presidente en Kaizen Bioscience LLC .
Perfil
Keith-Harrison Dewedoff is currently the Chairman at Kaizen Bioscience LLC and the Chief Financial Officer at Ceptur Therapeutics, Inc. He previously worked as the Chief Financial Officer at Danforth Advisors LLC and Code Biotherapeutics, Inc. In 2023, he briefly served as the Chief Financial Officer at NLS Pharmaceutics Ltd.
Cargos activos de Keith-Harrison Dewedoff
Empresas | Cargo | Inicio |
---|---|---|
Kaizen Bioscience LLC
Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Presidente | - |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Director Financiero/CFO | - |
Antiguos cargos conocidos de Keith-Harrison Dewedoff.
Empresas | Cargo | Fin |
---|---|---|
NLS PHARMACEUTICS LTD. | Director Financiero/CFO | 01/09/2023 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Director Financiero/CFO | - |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Director Financiero/CFO | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NLS PHARMACEUTICS LTD. | Health Technology |
Empresas privadas | 4 |
---|---|
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Finance |
Kaizen Bioscience LLC
Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Keith-Harrison Dewedoff